Lead Product(s) : DA-1241
Therapeutic Area : Endocrinology
Study Phase : Phase I
Recipient : Dong-A ST Co., Ltd.
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the license agreement, NeuroBo has obtained an exclusive license to develop and commercialize DA-1241 (a novel GPR119 agonist) and DA-1726, which are currently being evaluated for the treatment of nonalcoholic steatohepatitis (NASH), obesity and ty...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 11, 2022
Lead Product(s) : DA-1241
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Recipient : Dong-A ST Co., Ltd.
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Gemcabene
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 26, 2015
Lead Product(s) : Gemcabene
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
